# FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-amivantamab-vmjw-for-egfr-exon-20-insertion-mutated-non-small-cell-2beec4d9338a3291
Kind: policy · Impact: medium

## In brief

- The FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed.
- The approval covers first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
- The FDA announcement is dated 2026-11-07 in the source feed, but the approval itself is dated March 1, 2024.

## Why it matters

It gives a first-line targeted treatment option, combined with standard chemotherapy, for a subset of lung cancer patients with EGFR exon 20 insertion mutations. Readers covering oncology should note the approval date given in the source differs from the feed date.

## Timeline

- 2024-03-01: FDA approves amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed for first-line EGFR exon 20 insertion-mutated NSCLC

## Coverage

- [FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications](http://www.fda.gov/drugs/cancer-approvals/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications) — What's New: Drugs RSS Feed, 2026-11-07

Tags: oncology, lung cancer, drug approval, egfr, targeted therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science